Fucoxanthin Holds Potential to Become a Drug Adjuvant in Breast Cancer Treatment: Evidence from 2D and 3D Cell Cultures

Detalhes bibliográficos
Autor(a) principal: Malhão, Fernanda
Data de Publicação: 2021
Outros Autores: Macedo, Ana Catarina, Costa, Carla, Rocha, Eduardo, Ramos, Alice Abreu
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: http://hdl.handle.net/10400.18/8073
Resumo: (This article belongs to the Special Issue Compounds from Marine Sources as Hits and Leads for Pharmaceutical, Cosmeceutical and Industrial Applications)
id RCAP_fd69dd7ef93a0dfcc07f04e1b4d2ca15
oai_identifier_str oai:repositorio.insa.pt:10400.18/8073
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling Fucoxanthin Holds Potential to Become a Drug Adjuvant in Breast Cancer Treatment: Evidence from 2D and 3D Cell CulturesCisplatinCombinatorial TherapyDoxorubicinFucoxanthinSeaweed CompoundsTriple-Negative Breast Cancer(This article belongs to the Special Issue Compounds from Marine Sources as Hits and Leads for Pharmaceutical, Cosmeceutical and Industrial Applications)Fucoxanthin (Fx) is a carotenoid derived from marine organisms that exhibits anticancer activities. However, its role as a potential drug adjuvant in breast cancer (BC) treatment is still poorly explored. Firstly, this study investigated the cytotoxic effects of Fx alone and combined with doxorubicin (Dox) and cisplatin (Cis) on a panel of 2D-cultured BC cell lines (MCF7, SKBR3 and MDA-MB-231) and one non-tumoral cell line (MCF12A). Fucoxanthin induced cytotoxicity against all the cell lines and potentiated Dox cytotoxic effects towards the SKBR3 and MDA-MB-231 cells. The combination triggering the highest cytotoxicity (Fx 10 µM + Dox 1 µM in MDA-MB-231) additionally showed significant induction of cell death and genotoxic effects, relative to control. In sequence, the same combination was tested on 3D cultures using a multi-endpoint approach involving bioactivity assays and microscopy techniques. Similar to 2D cultures, the combination of Fx and Dox showed higher cytotoxic effects on 3D cultures compared to the isolated compounds. Furthermore, this combination increased the number of apoptotic cells, decreased cell proliferation, and caused structural and ultrastructural damages on the 3D models. Overall, our findings suggest Fx has potential to become an adjuvant for Dox chemotherapy regimens in BC treatment.The Strategic Funding UIDB/04423/2020 and UIDP/04423/2020 partially supported this research, through national funds provided by FCT and ERDF to CIIMAR/CIMAR, in the framework of the program PT2020. The Doctoral Program in Biomedical Sciences, of the ICBAS-University of Porto, offered additional funds.MDPIRepositório Científico do Instituto Nacional de SaúdeMalhão, FernandaMacedo, Ana CatarinaCosta, CarlaRocha, EduardoRamos, Alice Abreu2022-07-06T15:56:42Z2021-07-152021-07-15T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10400.18/8073engMolecules. 2021 Jul 15;26(14):4288. doi: 10.3390/molecules26144288.1420-304910.3390/molecules26144288info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2023-07-20T15:42:24Zoai:repositorio.insa.pt:10400.18/8073Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T18:42:48.328409Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv Fucoxanthin Holds Potential to Become a Drug Adjuvant in Breast Cancer Treatment: Evidence from 2D and 3D Cell Cultures
title Fucoxanthin Holds Potential to Become a Drug Adjuvant in Breast Cancer Treatment: Evidence from 2D and 3D Cell Cultures
spellingShingle Fucoxanthin Holds Potential to Become a Drug Adjuvant in Breast Cancer Treatment: Evidence from 2D and 3D Cell Cultures
Malhão, Fernanda
Cisplatin
Combinatorial Therapy
Doxorubicin
Fucoxanthin
Seaweed Compounds
Triple-Negative Breast Cancer
title_short Fucoxanthin Holds Potential to Become a Drug Adjuvant in Breast Cancer Treatment: Evidence from 2D and 3D Cell Cultures
title_full Fucoxanthin Holds Potential to Become a Drug Adjuvant in Breast Cancer Treatment: Evidence from 2D and 3D Cell Cultures
title_fullStr Fucoxanthin Holds Potential to Become a Drug Adjuvant in Breast Cancer Treatment: Evidence from 2D and 3D Cell Cultures
title_full_unstemmed Fucoxanthin Holds Potential to Become a Drug Adjuvant in Breast Cancer Treatment: Evidence from 2D and 3D Cell Cultures
title_sort Fucoxanthin Holds Potential to Become a Drug Adjuvant in Breast Cancer Treatment: Evidence from 2D and 3D Cell Cultures
author Malhão, Fernanda
author_facet Malhão, Fernanda
Macedo, Ana Catarina
Costa, Carla
Rocha, Eduardo
Ramos, Alice Abreu
author_role author
author2 Macedo, Ana Catarina
Costa, Carla
Rocha, Eduardo
Ramos, Alice Abreu
author2_role author
author
author
author
dc.contributor.none.fl_str_mv Repositório Científico do Instituto Nacional de Saúde
dc.contributor.author.fl_str_mv Malhão, Fernanda
Macedo, Ana Catarina
Costa, Carla
Rocha, Eduardo
Ramos, Alice Abreu
dc.subject.por.fl_str_mv Cisplatin
Combinatorial Therapy
Doxorubicin
Fucoxanthin
Seaweed Compounds
Triple-Negative Breast Cancer
topic Cisplatin
Combinatorial Therapy
Doxorubicin
Fucoxanthin
Seaweed Compounds
Triple-Negative Breast Cancer
description (This article belongs to the Special Issue Compounds from Marine Sources as Hits and Leads for Pharmaceutical, Cosmeceutical and Industrial Applications)
publishDate 2021
dc.date.none.fl_str_mv 2021-07-15
2021-07-15T00:00:00Z
2022-07-06T15:56:42Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/10400.18/8073
url http://hdl.handle.net/10400.18/8073
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv Molecules. 2021 Jul 15;26(14):4288. doi: 10.3390/molecules26144288.
1420-3049
10.3390/molecules26144288
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv MDPI
publisher.none.fl_str_mv MDPI
dc.source.none.fl_str_mv reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799132173706461184